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Thank you, Professor de Wardener for your kind com-
ments as well as your support and friendship for many
years. I appreciate the honor of sharing the Jean Ham-
burger Award for clinical research from the Interna-
tional Society of Nephrology with my friend Stewart
Cameron. I accept the Jean Hamburger Award on behalf
of over 100 fellows from 27 countries who have worked
and published with me for more than 30 years. There
have been several major areas of our research that have
focused on important clinical problems, including acute
renal failure (ARF), arginine vasopressin (AVP) and
body fluid volume regulation, autosomal-dominant poly-
cystic kidney disease (ADPKD), and type 2 diabetic
complications.
ACUTE RENAL FAILURE
Our ARF studies focused on the pathogenic role of
increased cytosolic calcium concentration in tubular epi-
thelial and vascular smooth muscle cells (VSMC). In
proximal tubular epithelial cells (PTC), ischemic injury
was associated with increased Ca2 influx, mitochondrial
Ca2 overload, and impaired respiration. Subsequently,
the Ca2-dependent protein, calpain, was found to be
activated in PTC during hypoxia and associated with
tubular injury. A relationship between activation of cal-
pain and caspases also occurred in hypoxic PTC, thereby
leading to caspase and interleukin-18 (IL-18)–related in-
jury. A rise in glomerular afferent arteriole Ca2 concen-
tration also occurred during renal ischemia and was asso-
ciated not only with loss of autoregulation but also
increased sensitivity to angiotensin II (Ang II) and endo-
thelin (ET). These vascular renal effects could be mark-
edly attenuated with atrial natremic peptide (ANP) in
the isolated ischemic perfused rat kidney or with intrare-
nal ANP in humans. Systemic ANP, however, was associ-
ated with declines in mean arterial flow pressure (MAP)
in prospective randomized negative studies in patients
with ARF; the systemic hypotensive effect of ANP may
have obscured any beneficial renal effect.
With renal ischemia and hypoxia or sepsis, nitric oxide
(NO) was shown to have a deleterious effect on tubules,
in part by combining with reactive oxygen species (ROS)
to form the injurious compound, peroxynitrite. On the
other hand, the vasodilating effect of NO has been shown
to be protective against ischemic injury.
In sepsis-related ARF, the early (16 hours after lipo-
polysaccharide) phase appears to be related to increased
endogenous vasoconstrictors, including norepenephine
(NE), Ang II, and ET, which attenuate the systemic
vasodilating effect of NO at the expense of secondary
renal vasoconstriction. Oxygen radical scavengers and
blockade of tumor necrosis factor-alpha (TNF-) were
also shown to be beneficial early in experimental sepsis-
related ARF. The later proinflammatory phase of sepsis-
related ARF involves cytokine and chemokine activation
associated with cellular infiltration.
NONOSMOTIC RELEASE OF AVP AND BODY
FLUID VOLUME REGULATION
AVP release was shown to occur independent of os-
molality and to be baroreceptor-mediated in settings of
arterial underfilling secondary to either a decrease in
stroke volume and/or arterial vasodilation. Thus, the
term nonosmotic AVP release was coined. Further stud-
ies in experimental and human cardiac failure, cirrhosis,
and pregnancy demonstrated an increase in radioimmu-
noassayable AVP despite a degree of hypoosmolality,
which would maximally suppress plasma AVP in normal
subjects. The use of V2 vasopressin antagonists were
shown to reverse the water retention, thus confirming
the role of nonosmotic AVP release in edematous disor-
ders. In experimental and human cardiac failure the non-
osmotic AVP release up-regulated aquaporin 2 (AQP-2)
water channels, an effect which could be reversed in the
renal papilla and urine, respectively, with orally active,
nonpeptide V2 antagonists. The arterial underfilling in
cirrhosis and pregnancy occurred secondary to arterial
vasodilation, which was mediated, at least in part, by NO.
In this regard, nitric oxide synthase (NOS) inhibition
was shown to profoundly reverse the sodium and water
retention in experimental cirrhosis. The failure to escape
from the sodium-retaining effects of aldosterone and
the resistance to ANP in edematous disorders was most
consistent with diminished fluid delivery to the distal
sites of action of aldosterone and ANP, an effect which
occurred secondary to activation of the neurohumerol
axis in response to arterial underfilling. Other studies
documented the role of Ca2 and opioids in the non-
osmotic release of AVP, and incriminated nonosomotic





The accumulation of the largest population of
ADPKD patients in the world allowed the delineation of
the natural history of this most frequent, life-threatening,
hereditary renal disease affecting 12 million patients
worldwide. The most treatable complication was found
to be the early onset of hypertension at a mean age of
29 years, which occurs prior to loss of renal function.
When compared with essential hypertension patients,
the renin-angiotensin-aldosterone system (RAAS) was
significantly more activated in patients with ADPKD.
Moreover, in ADPKD left ventricular hypertrophy
(LVH) was found to have a frequency of 50% at age 40
years, an important clinical finding since in the era of
renal replacement therapy cardiovascular complications
have become the most frequent cause of death in
ADPKD patients. The hypertension in ADPKD patients
correlates with the degree of kidney enlargement and the
rate of progression to end stage renal disease (ESRD).
Angiotension converting enzyme inhibitors (ACEI) were
shown to have a significantly greater reversal of LVH
and antiproteinuric effect than calcium channel blocker
(CCB) in the ADPKD patient. Aggressive blood pres-
sure control to a goal of 125/75 mm Hg was found in a
7-year prospective randomized study to more signifi-
cantly reverse LVH in ADPKD patients as compared
to a blood pressure goal of 135/85 mm Hg. In an epidemi-
ologic study, the progression rate of ADPKD to ESRD
was shown to be significantly slower in the most recent
decade as compared to the previous decade; the only
detectable differences were the more frequent use of
ACEI therapy and better blood pressure control in the
recent time period. Insight into the phenotypic hetero-
geneity of ADPKD in the same family, and thus with
the same mutation, has been found to be influenced
by the prevalence of parenteral hypertension and other
modifying genes. On this background, a clinical ADPKD
network has been formed by the National Institutes of
Health (NIH) to examine the effect of RAAS blockade
on early and advanced ADPKD on renal cystic growth
and rate of renal functional deterioration, respectively.
APPROPRIATE BLOOD PRESSURE
CONTROL IN TYPE 2 DIABETES
MELLITUS (ABCD) TRIAL
As with ADPKD, our studies in diabetes mellitus were
primarily undertaken in patients, particularly the pro-
spective randomized ABCD trial in 950 type 2 diabetes
patients. The hypertensive (140/90 mm Hg for average
of 12 years) cohort study included 470 patients, while
the normotensive study included 480 patients followed
for 5 years. In addition to comparing standard (140/90
mm Hg) versus aggressive (130/80 mm Hg) blood pres-
sure control, the affect of ACEI versus CCBs was also
examined relative to renal, cardiovascular, eye, and neu-
rological complications. The hypertensive ABCD study
demonstrated (1) stable renal function with both levels
of blood pressure control in normoalbuminuric and mi-
croalbumuric patients, (2) decreased myocardial infarc-
tions with ACEI versus CCB, (3) 5 mL/min/year de-
crease in renal function with both blood pressure goals
in patients with overt diabetic nephropathy, and (4) de-
creased mortality with the more aggressive blood pres-
sure control. In the normotensive ABCD cohort, there
were no differences between the ACEI and CCB treat-
ments; however, the more aggressive blood pressure con-
trol demonstrated significantly (1) decreased progres-
sion to incipient nephropathy (30 to 300 mg/day albumin
excretion), (2) decreased progression from incipient to
overt nephropathy (300 mg/day albumin excretion),
(3) decreased progression of retinopathy, and (4) de-
creased incidence of strokes. In type 2 patients with
peripheral vascular disease, the more aggressive blood
pressure control was associated with a significant de-
crease in cardiovascular complications.
The opportunity to work with fellows from numerous
countries over the more than 30 years has been an ex-
tremely productive, rewarding, and enjoyable experi-
ence. I am honored to accept the Jean Hamburger Award
for contributions in research with a particular emphasis
on patient-oriented investigations on behalf of these re-
search fellows.
Finally, the love and support of Barbara and my family
have been the primary foundation for both my profes-
sional and personal life.
